Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05136755

NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder

Sponsor: China Medical University Hospital

Updated 6 times since 2021 Last updated: Feb 16, 2025 Started: Jan 25, 2022 Primary completion: Nov 30, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05136755, this PHASE2 trial focuses on Major Depressive Disorder and remains actively recruiting participants. Sponsored by China Medical University Hospital, it has been updated 6 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Mar 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2023 — Jul 2024 [monthly]

Recruiting PHASE2
Feb 2022 — Mar 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Dec 2021 — Feb 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

China Medical University Hospital

Data source: China Medical University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taichung, Taiwan